On June 22, 2021, Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million Series C financing led by Warburg Pincus. The financing included participation by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, and Baidu Ventures and new investors including CPE, Hillhouse Capital, OrbiMed, Mirae Asset, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China, and Sage Partners.

Proceeds from the financing will be used to progress InSilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

The Wilson Sonsini team that represented InSilico Medicine in this transaction includes:

Corporate
Jie Zhu, Partner
Barry Taylor, Partner
Xuchao Dong, Counsel
Helen Wang, Associate
TJ Tingjie Li, Associate
Yiwen Feng, Special Associate

Tax
Jonathan Zhu, Partner
Nika Antonikova, Associate

Patents and Innovations
Karen Wong, Senior Of Counsel
Michael Hostetler, Partner
Scott L. Burkette, Senior Counsel
Bo Chen, IP Specialist

Regulatory
Stephen R. Heifetz, Partner
David M. Hoffmeister, Partner
Eva F. Yin, Associate

Employee Benefits and Compensation
Sriram Krishnamurthy, Partner

For more information, please see Insilico Medicine’s press release.